About The Cover

ONLINE COVER Missing the Target. Although targeted treatment now plays a prominent role in oncology, many of the therapeutics in preclinical development never reach clinical approval. Lin et al. identified one potential cause for this problem, showing that some of the compounds in clinical development do not actually target the oncogenes they were originally thought to target. The authors also demonstrated how gene editing technology can help validate drug targets and determined the real target of one previously mischaracterized compound, suggesting that other drug candidates could require similar reclassification. [CREDIT: JULIA KUHL]